Upsher-Smith acquires 20 generics from Sandoz

MAPLE GROVE, Minn. — Upsher-Smith Laboratories announced Tuesday that it had acquired 20 U.S. generic products from Sandoz for an upfront cash payment and additional payments contingent on product sales. The terms of the transaction were not disclosed. 

 

“Upsher-Smith is pleased to build upon our long-standing strategic relationship with an industry leader, Sandoz,” Upsher-Smith president Rusty Field said. “This new agreement is another example of our focus on and ability to execute significant acquisitions that leverage our internal capabilities and expand our portfolio of quality, high-value generic products for patients.”

 

The portfolio Upsher-Smith acquires contains 19 solid-oral dosage products and one nasal product, all of which have been approved by the Food and Drug Administration but haven’t been marketed by Sandoz. The total annual product sales, according to IMS Health data for the 12 months ended July 2016, is about $400 million.